Novo Nordisk commits $285M to launch alliance on longer-acting GLP-1s

The latest stories trending on MedCity News.

Editor's Pick

Top Story Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs The Novo Nordisk/Ascendis partnership's lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. Sponsored Tackling the Rise of Healthcare Costs for Employers Presented by Personify Health With the cost of healthcare rising, how are employers facing that challenge and still prioritize employee health and well being?  Register today and discover actionable insights and pragmatic solutions to address the ongoing budget battle for your company. Be Part of the Leading Investment Event of 2025 Meet and mingle with investors, innovators, and thought leaders at INVEST 2025, taking place at 333 North Green in the heart of Chicago.  Seize the opportunity to elevate your investment game. Get your tickets today and join us on 29-30 April, 2025. Register Now To Secure Lowest Rate

Featured News

Reducing Clinical and Staff Burnout with AI Automation As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers. 5 Interesting Companies I Saw at HLTH I met a mix of biotech and healthtech companies at HLTH affecting everything from drug development, drug efficacy to controlling specialty care costs and managing chronic diseases. Is There Still a Place for Point Solutions? One Investor Weighs In There are some areas where point solutions make a lot of sense, such as when they're focused on a condition without a lot of comorbidities, according to one healthcare expert. Viking Therapeutics' Early Clinical Data Continue to Build Case for Its Oral Obesity Drug Higher doses of a Viking Therapeutics pill that targets two receptors led to greater weight loss without worsening safety or tolerability, according to Phase 1 results presented during the ObesityWeek conference. Meanwhile, an injectable version of this Viking drug is on track to Phase 3 testing. Why AI Governance Is the Number 1 Issue on This Health System Exec's Mind Jason Hill, Ochsner Health's innovation officer, said he goes to sleep most nights and wakes up most morning worried about one thing: the state of generative AI governance in healthcare. To him, providers and other healthcare organizations are in dire need of frameworks to ensure their AI tools are safe and perform well over time. Imaging Practices Can Restore Their Clinicians' Cybersecurity Confidence With These Four Steps Steps that healthcare providers can take – internally and with the help of external partners – to boost both their security capabilities and the confidence of their clinicians in those capabilities  A Recipe for Better Obesity Care: Integrating GLP-1s with Food as Medicine Nutrition isn't a supplement — it's foundational to metabolic health. It's time we integrate more 'Food as Medicine' initiatives alongside the GLP-1 therapies that are gaining traction.

Resources

SPONSORED Telemedicine Software Pricing Guide How do you know if you're spending too much or too little on Telemedicine software? This guide from Software Advice breaks down upfront, subscription and hidden costs, plus answers other questions you've been wondering about. Get Your Free Pricing Guide Now

MedCity News • PO Box 901 • New York, NY unsubscribe